Neuphoria Therapeutics (NEUP) EBIAT (2024 - 2025)
Neuphoria Therapeutics (NEUP) has disclosed EBIAT for 2 consecutive years, with $1.9 million as the latest value for Q4 2025.
- Quarterly EBIAT rose 198.11% to $1.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$5.6 million through Dec 2025, changed N/A year-over-year, with the annual reading at -$400000.0 for FY2025, 97.42% up from the prior year.
- EBIAT for Q4 2025 was $1.9 million at Neuphoria Therapeutics, up from -$9.9 million in the prior quarter.
- The five-year high for EBIAT was $11.3 million in Q1 2025, with the low at -$9.9 million in Q3 2025.